Odyssey Therapeutics (ODTX) Morgan Stanley 24th Annual Global Healthcare Conference summary

Strategic vision and company evolution

• Transitioned to public markets to support a broad portfolio and multiple modalities, enabling work on both small molecules and biologics for immunology and inflammation.

• Focused on upstream targets to achieve deep, durable remissions in large patient populations, leveraging recent biological insights.

• Plans to commercialize select drugs independently while partnering for broader indications, aiming for rapid innovation and impactful medicines over the next 5-10 years.

• Robust internal discovery platform enables rapid progression from target identification to clinical studies, enhancing capital efficiency and competitiveness.

OD-001 (RIPK2 inhibitor) clinical and development highlights

• Phase IIa open-label study showed 27% clinical remission in IBD, with consistent biomarker, histology, and endoscopic improvements.

• Maintains efficacy in patients previously treated with advanced therapies, addressing a key unmet need in refractory IBD.

• Rapid onset of action observed, with patient responses within weeks, differentiating from most biologics.

• Combination studies with vedolizumab (ENTYVIO) planned, leveraging orthogonal mechanisms for potentially synergistic effects.

• Multiple clinical readouts expected by end of 2027, including monotherapy and combination trials, with updates on exploratory biomarkers and dose response.

Pipeline expansion and novel targets

• OD-002 targets SLC15A4, a pathway critical for interferon production and pathogenic B cell maturation, with plans to file CTA and initiate phase I in the coming year.

• SLC15A4 inhibition offers potential in lupus and other interferonopathies, with basket trial strategy and early proof-of-concept in cutaneous lupus.

• OD-004 is a bispecific biologic targeting TSLP and IL-33, designed for synergistic effects in non-type two respiratory diseases, leveraging genetic insights.

• TNFR2 biologic program aims to generate high-quality regulatory T cells for broad immunosuppressive applications, currently in GLP toxicology.